文献速递眼底病与葡萄膜炎神经眼科

小胶质细胞Sfrp2抑制S100a8介导的神经炎症并保护视网膜缺血再灌注损伤

Sfrp2 in Microglia Inhibited S100a8-Mediated Neuroinflammation and Protected Neural Damage Following Retinal Ischemia-Reperfusion.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

该研究在小鼠视网膜缺血再灌注(I/R)模型和脂多糖刺激的BV2细胞模型中,探究Sfrp2的表达、定位与功能。结果显示Sfrp2在小胶质细胞中高表达,其缺失加重视网膜结构损伤、内层视网膜神经元变性、视功能障碍及炎症;机制上Sfrp2缺失通过促进TRAF6-TAK1复合物形成激活TRAF6-TAK1-NF-κB通路,上调S100a8,而S100a8抑制剂可部分减轻损伤。

要点

  • Sfrp2在I/R视网膜的小胶质细胞中高表达,其缺失加重损伤。
  • Sfrp2缺失经TRAF6-TAK1-NF-κB通路上调S100a8。
  • S100a8抑制剂可部分缓解小胶质细胞Sfrp2缺失所致视网膜损伤。

核心结论

  • 小胶质细胞Sfrp2通过抑制TRAF6-TAK1-NF-κB通路及下游S100a8减轻神经炎症并保护I/R视网膜。
  • Sfrp2可能成为缺血性视网膜病变中神经元变性的保护策略。

研究设计与样本

  • 建立小鼠视网膜I/R体内模型和脂多糖刺激的BV2细胞体外模型。
  • 用Cre-lox在小鼠视网膜小胶质细胞条件性敲除Sfrp2,用siRNA在BV2细胞敲低Sfrp2。
  • 用免疫组化、Western blotting评估人视网膜组织与I/R模型中Sfrp2表达,免疫荧光定位。
  • 用HE染色、免疫荧光、TUNEL染色评估视网膜结构、内层视网膜神经元存活与细胞凋亡。
  • 用视网膜电图评估视网膜功能,用RNA测序、WB和免疫沉淀解析机制。

主要发现

  • Sfrp2在遭受I/R损伤的视网膜中高表达,并定位于I/R模型的小胶质细胞。
  • 小胶质细胞Sfrp2缺失加重I/R模型的视网膜结构损伤、内层视网膜神经元变性、视功能障碍及小胶质细胞介导的炎症。
  • Sfrp2缺失通过促进TRAF6-TAK1复合物形成激活TRAF6-TAK1-NF-κB信号级联,增加下游炎症介质S100a8表达。
  • S100a8抑制剂可部分减轻I/R后小胶质细胞Sfrp2缺失诱导的视网膜损伤。

临床怎么用

  • 本研究为动物与细胞实验,尚不能直接给出临床诊疗推荐。
  • 提示Sfrp2-S100a8轴可能作为缺血性视网膜病变神经保护研究的候选靶点。

局限性

  • 证据来自小鼠I/R模型与BV2细胞,尚未在临床人群验证。
  • S100a8抑制剂仅部分减轻损伤,提示还有其他机制参与。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to explore retinal Sfrp2 expression, functional roles, and underlying mechanism in retinal ischemia reperfusion (I/R). METHODS: We established an I/R mouse model in vivo and a lipopolysaccharide-stimulated BV2 model in vitro. Immunohistochemistry and Western blotting (WB) assessed Sfrp2 expression in human retinal tissue, and WB further evaluated its expression in I/R model. Immunofluorescence staining was used to define its localization. Sfrp2 expression was ablated by Cre-lox mediated conditional deletion in mouse retinal microglia and by siRNA-mediated knockdown in BV2 cells. Hematoxylin and eosin staining, immunofluorescence, and TUNEL staining were applied for evaluating retinal structure, survival of inner retinal neurons, and cell apoptosis, respectively. Retinal function was evaluated by electroretinography. RNA-sequencing, WB, and immunoprecipitation were used to elucidate the underlying mechanisms. RESULTS: Sfrp2 was highly expressed in the retina subjected to I/R injury. Sfrp2 was shown to localize in microglia in an I/R model. Correspondingly, microglial Sfrp2 deficiency exacerbated the retinal structural damage, inner retinal neuronal degeneration, visual dysfunction, and microglia-mediated inflammation in the I/R model. Mechanistically, Sfrp2 deficiency activated TRAF6-TAK1-NF-κB signaling cascade by promoting the TRAF6-TAK1 complex formation, subsequently increasing the expression of downstream inflammatory mediator S100a8. Importantly, S100a8 inhibitor could partially mitigate the retinal injury induced by microglial Sfrp2 deficiency following I/R. CONCLUSIONS: Sfrp2 in microglia inhibits TRAF6-TAK1-NF-κB signaling pathway and downstream inflammatory mediator S100a8 thereby attenuating neuroinflammation and protecting the retina in I/R. Sfrp2 may represent a protective strategy for neuronal degeneration in ischemic retinopathy.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Tao S, Hu W, Hu Y, et al. Sfrp2 in Microglia Inhibited S100a8-Mediated Neuroinflammation and Protected Neural Damage Following Retinal Ischemia-Reperfusion. Invest Ophthalmol Vis Sci. 2026. PMID: 41784333. doi:10.1167/iovs.67.3.8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。